Patents Assigned to TheraVida, Inc.
  • Patent number: 11779569
    Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: October 10, 2023
    Assignee: TheraVida, Inc.
    Inventor: Benjamin F. McGraw, III
  • Patent number: 11185533
    Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 30, 2021
    Assignee: THERAVIDA, INC.
    Inventor: Benjamin F. McGraw, III
  • Patent number: 10786457
    Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: September 29, 2020
    Assignee: THERAVIDA, INC.
    Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
  • Patent number: 10610519
    Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 7, 2020
    Assignee: THERAVIDA, INC.
    Inventor: Benjamin F. McGraw, III
  • Patent number: 10328057
    Abstract: Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 25, 2019
    Assignee: THERAVIDA, INC.
    Inventor: Benjamin F. McGraw, III
  • Patent number: 9968556
    Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 15, 2018
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
  • Patent number: 9744157
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: August 29, 2017
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
  • Patent number: 9415013
    Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 16, 2016
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
  • Patent number: 9132124
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 15, 2015
    Assignee: THERAVIDA, INC.
    Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
  • Patent number: 8940763
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: January 27, 2015
    Assignee: TheraVida, Inc.
    Inventors: Mehdi Paborji, Wendy Jade Limayo Hernandez, Kenneth L. Duchin, Roger S. Flugel
  • Publication number: 20140194454
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicant: TheraVida, Inc.
    Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
  • Publication number: 20140105976
    Abstract: Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 17, 2014
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Robert V. TUOHY, Stephen P. LEVINE, Dana E. MOSESON, Nicolas D. KIRKLAND
  • Publication number: 20130296392
    Abstract: Disclosed herein are methods of treating overactive bladder in a patient, the method comprising identifying a patient in need thereof; and administering to the patient a composition comprising tolterodine, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, wherein after the administration Cmax for tolterodine is between 1.0-8.0 ng/mL.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 7, 2013
    Applicant: TheraVida, Inc.
    Inventors: Mehdi PABORJI, Roger S. FLUGEL, Kenneth L. DUCHIN
  • Patent number: 8470864
    Abstract: Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: June 25, 2013
    Assignee: Theravida, Inc.
    Inventor: Mehdi Paborji
  • Publication number: 20120289563
    Abstract: Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Wendy Jade Limayo HERNANDEZ, Kenneth L. DUCHIN, Roger S. FLUGEL
  • Publication number: 20120289564
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
  • Publication number: 20120289529
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
  • Publication number: 20120289560
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL
  • Publication number: 20120289543
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Wendy Jade Limayo HERNANDEZ, Kenneth L. DUCHIN, Roger S. FLUGEL
  • Publication number: 20120289567
    Abstract: Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 15, 2012
    Applicant: THERAVIDA, INC.
    Inventors: Mehdi PABORJI, Kenneth L. DUCHIN, Wendy Jade Limayo HERNANDEZ, Roger S. FLUGEL